Search results
Once the diagnostic work-up of sarcoidosis is completed, the physician has to decide whether treatment is necessary, balancing the trade-offs between pros and cons. Sarcoidosis may have a self-limiting course without any negative impact on quality of life or prognosis, whereas prolonged use of systemic glucocorticoids (GCs), the pharmacological ...
8 wrz 2021 · The decision of whether (and, if so, when) to treat an individual patient who has sarcoidosis depends on two major factors: the risk of organ failure or death and the extent to which the...
15 wrz 2021 · Significant gaps currently exist in the understanding of these high-risk manifestations of sarcoidosis, including their natural history, diagnostic criteria, biomarkers, and the treatment strategy, such as the ideal agent, optimal dose, and treatment duration.
This review focuses on APS and its management, adding to the recent practice guidelines/statements on the diagnosis of sarcoidosis , pulmonary sarcoidosis , and antiinflammatory treatment of sarcoidosis .
29 lis 2022 · In these cases, the pros and cons of treatment and threat to organ function should be evaluated on a case-by-case basis. Patients with sarcoidosis can have debilitating symptoms such as fatigue and muscle aches which significantly impact their quality of life.
Treatment is directed at alleviating organ dysfunction, preventing irreversible scarring, and improving quality of life. Herein, we review the indications for treatment, pharmacotherapy, treatment duration, side effects, adjunct non-pharmacologic therapies, and outcomes for patients.
Biomarkers could benefit sarcoidosis care in several ways: diagnosis, assessment of severity, prediction of disease behavior, prognosis, response to treatment, and relapse. Unfortunately, none of the available biomarkers are sufficiently sensitive or specific to be routinely used in clinical practice.
